monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.
Company profile
Ticker
MNPR
Exchange
Website
CEO
Chandler Drew Robinson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Monopar Therapeutics Australia Ltd • Monopar Therapeutics, SARL ...
IRS number
320463781
MNPR stock data
Latest filings (excl ownership)
8-K
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
16 Apr 24
8-K
Regulation FD Disclosure
10 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Monopar Reports Fourth Quarter and Full-Year 2023
28 Mar 24
8-K
Regulation FD Disclosure
7 Mar 24
8-K
Monopar Announces Positive Preclinical Therapeutic Isotope Data
5 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Feb 24
8-K
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
27 Feb 24
8-K
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
22 Feb 24
8-K
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical
20 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.52 mm | 5.52 mm | 5.52 mm | 5.52 mm | 5.52 mm | 5.52 mm |
Cash burn (monthly) | 566.47 k | 733.43 k | 688.66 k | 819.02 k | 646.60 k | 634.52 k |
Cash used (since last report) | 3.86 mm | 5.00 mm | 4.69 mm | 5.58 mm | 4.41 mm | 4.32 mm |
Cash remaining | 1.66 mm | 517.33 k | 822.36 k | -65.96 k | 1.11 mm | 1.19 mm |
Runway (months of cash) | 2.9 | 0.7 | 1.2 | -0.1 | 1.7 | 1.9 |
Institutional ownership, Q2 2023
1.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 2 |
Closed positions | 5 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 164.54 mm |
Total shares | 192.44 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 99.18 k | $84.80 mm |
Geode Capital Management | 41.89 k | $35.82 mm |
Millennium Management | 32.76 k | $28.01 mm |
Rappaport Reiches Capital Management | 10.70 k | $9.14 mm |
MS Morgan Stanley | 4.00 k | $3.42 mm |
Tower Research Capital | 3.73 k | $3.19 mm |
FMR | 150.00 | $128.00 k |
WFC Wells Fargo & Co. | 33.00 | $28.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Andrew Cittadine | Common Stock | Payment of exercise | Dispose F | No | No | 0.681 | 3,098 | 2.11 k | 57,624 |
31 Mar 24 | Andrew Cittadine | Common Stock | Option exercise | Acquire M | No | No | 0 | 8,952 | 0.00 | 60,722 |
31 Mar 24 | Andrew Cittadine | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 8,952 | 0.00 | 82,223 |
31 Mar 24 | Kim R Tsuchimoto | Common Stock | Payment of exercise | Dispose F | No | No | 0.681 | 4,082 | 2.78 k | 50,470 |
31 Mar 24 | Kim R Tsuchimoto | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,956 | 0.00 | 54,552 |
31 Mar 24 | Kim R Tsuchimoto | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,956 | 0.00 | 84,369 |
31 Mar 24 | Chandler Robinson | Common Stock | Payment of exercise | Dispose F | No | No | 0.681 | 7,172 | 4.88 k | 166,130.8 |
31 Mar 24 | Chandler Robinson | Common Stock | Option exercise | Acquire M | No | No | 0 | 24,474 | 0.00 | 173,302.8 |
31 Mar 24 | Chandler Robinson | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 24,474 | 0.00 | 197,811 |
1 Jan 24 | Patrice Rioux | Stock Options Common Stock | Grant | Acquire A | No | No | 0.3402 | 10,000 | 3.40 k | 10,000 |
News
Monopar Announces Radiopharma Presentation Selected For Society Of Nuclear Medicine And Molecular Imaging 2024 Annual Meeting
18 Apr 24
Monopar Announces Filing Of Patent Protecting MNPR-101 Radiopharma Optimization Findings
16 Apr 24
JonesTrading Upgrades Monopar Therapeutics to Buy, Announces $2 Price Target
11 Apr 24
Recap: Monopar Therapeutics Q4 Earnings
28 Mar 24
Monopar Therapeutics Q4 GAAP EPS $(0.12) Beats $(0.15) Estimate
28 Mar 24
Press releases
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
16 Apr 24
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
10 Apr 24
Thinking about buying stock in Monopar Therapeutics, Aquestive Therapeutics, NXU, SeaStar Medical, or TDCX?
1 Mar 24
Thinking about buying stock in Monopar Therapeutics, AMC Entertainment, Zyversa Therapeutics, MoneyHero, or Blink Charging?
27 Feb 24